# Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

> **NCT06232694** · NA · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 54 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;
- **DRUG:** Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;
- **OTHER:** utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).

## Key facts

- **NCT ID:** NCT06232694
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-01-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06232694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06232694, "Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06232694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*